Hypoglycaemia: Current management and controversies

Postgraduate Medical Journal

Volumn 87, Issue 1026, 2011, Pages 298-306

  Choudhary, Pratik ^a   Amiel, Stephanie A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHASIC INSULIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INCRETIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

AWARENESS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; COMORBIDITY; CONTINUOUS INFUSION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRIVING ABILITY; FRUIT JUICE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INTENSIVE CARE; LIFESTYLE MODIFICATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS TRANSPLANTATION; PATIENT ASSESSMENT; PATIENT EDUCATION; PREVALENCE; REVIEW; RISK ASSESSMENT; SPORTS DRINK; SUDDEN DEATH; TREATMENT DURATION;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; RISK FACTORS;

EID: 79953737150     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2008.068197     Document Type: Review

References (93)

1. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002;45:937-48.
2. Davis EA, Keating B, Byrne GC, et al. Impact of improved glycaemic control on rates of hypoglycaemia in insulin dependent diabetes mellitus. Arch Dis Child 1998;78:111-15.
3. DVLA. 'At a Glance Guide to the Current Medical Standards of Fitness to Drive'dA Guide for Medical Practitioners. DVLA, 2008. http://www.dvla.gov.uk/at_a_glance/ch3_diabetes.htm.
4. Leckie AM, Graham MK, Grant JB, et al. Frequency, severity, and morbidity of hypoglycemia occurring in the workplace in people with insulin-treated diabetes. Diabetes Care 2005;28:1333-8.
5. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-80.
6. NHS Information Centre. Hospital Episode Statistics. http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=206 (accessed Apr 2008).
7. Frier BM. Defining hypoglycaemia: what level has clinical relevance? Diabetologia 2009;52:31-4.
8. DCCT. Hypoglycemia in the diabetes control and complications trial. The diabetes control and complications trial research group. Diabetes 1997;46:271-86.
9. Bott S, Bott U, Berger M, et al. Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia 1997;40:926-32.
10. DAFNE Group. Training in flexible, intensive insulin management to enable dietary freedom in people with Type 1 diabetes: dose adjustment for normal eating (DAFNE) randomized controlled trial. Diabet Med 2003;20(Suppl 3):4-5.
11. Pedersen-Bjergaard U, Pramming S, Heller SR, et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 2004;20:479-86.
12. Pramming S, Thorsteinsson B, Bendtson I, et al. Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med 1991;8:217-22.
13. Ter Braak EW, Appelman AM, van de LM, et al. Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care 2000;23:1467-71.
14. Zammitt NN, Geddes J, Warren RE, et al. Serum angiotensin-converting enzyme and frequency of severe hypoglycaemia in Type 1 diabetes: does a relationship exist? Diabet Med 2007;24:1449-54.
15. UK Hypoglycemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7.
16. Geddes J, Schopman JE, Zammitt NN, et al. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med 2008;25:501-4.
17. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994;17:697-703.
18. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
19. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.
20. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drugnaive patients with type 2 diabetes. Horm Metab Res 2009;41:905-9.
21. Ukpds. UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia 1983;24:404-11.
22. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467-73.
23. Akram K, Pedersen-Bjergaard U, Carstensen B, et al. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a cross-sectional survey. Diabet Med 2006;23:750-6.
24. Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005;22:749-55.
25. Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care 2002;25:2109-10.
26. Johnson ES, Koepsell TD, Reiber G, et al. Increasing incidence of serious hypoglycemia in insulin users. J Clin Epidemiol 2002;55:253-9.
27. Yki-Jarvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999;130:389-96.
28. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995;18:1113-23.
29. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30.
30. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-47.
31. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.
32. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-55.
33. Cryer P. Hypoglycaemia. Pathophysiology, Diagnosis and Treatment. New York: Oxford University Press, 1997.
34. Amiel SA, Maran A, Powrie JK, et al. Gender differences in counterregulation to hypoglycaemia. Diabetologia 1993;36:460-4.
35. Davis SN, Shavers C, Costa F. Gender-related differences in counterregulatory responses to antecedent hypoglycemia in normal humans. J Clin Endocrinol Metab 2000;85:2148-57.
36. Banarer S, Cryer PE. Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia. Diabetes 2003;52:1195-203.
37. Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998;338:1657-62.
38. Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994;43:403-10.
39. Brierley EJ, Broughton DL, James OF, et al. Reduced awareness of hypoglycaemia in the elderly despite an intact counter-regulatory response. QJM 1995;88:439-45.
40. Henderson JN, Allen KV, Deary IJ, et al. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003;20:1016-21.
41. Meneilly GS, Cheung E, Tuokko H. Altered responses to hypoglycemia of healthy elderly people. J Clin Endocrinol Metab 1994;78:1341-8.
42. Jaap AJ, Jones GC, McCrimmon RJ, et al. Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin. Diabet Med 1998;15:398-401.
43. Spyer G, Hattersley AT, MacDonald IA, et al. Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes. Lancet 2000;356:1970-4.
44. Levy CJ, Kinsley BT, Bajaj M, et al. Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Diabetes Care 1998;21:1330-8.
45. Choudhary P, Lonnen K, Emery CJ, et al. Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulin- and sulphonylurea-treated Type 2 diabetes. Diabet Med 2009;26:665-72.
46. DCCT. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med 1991;90:450-9.
47. Pedersen-Bjergaard U, Gerholm-Larsen B, Pramming S, et al. Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus. Lancet 2001;357:1248-53.
48. Freathy RM, Lonnen KF, Steele AM, et al. The impact of the angiotensin-converting enzyme insertion/deletion polymorphism on severe hypoglycemia in Type 2 diabetes. Rev Diabet Stud 2006;3:76-81.
49. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
50. Heller SR. Abnormalities of the electrocardiogram during hypoglycaemia: the cause of the dead in bed syndrome? Int J Clin Pract 2002;(Suppl):27-32.
51. Gill GV, Woodward A, Casson IF, et al. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetesethe 'dead in bed' syndrome revisited. Diabetologia 2009;52:42-5.
52. Patel A, Macmahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
53. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
54. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 2008;24:87-92.
55. Cox DJ, Gonder-Frederick LA, Kovatchev BP, et al. Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction. Diabetes Care 2000;23:163-70.
56. Cox DJ, Gonder-Frederick L, Clarke W. Driving decrements in type I diabetes during moderate hypoglycemia. Diabetes 1993;42:239-43.
57. Cox DJ, Penberthy JK, Zrebiec J, et al. Diabetes and driving mishaps: frequency and correlations from a multinational survey. Diabetes Care 2003;26:2329-34.
58. Hansotia P, Broste SK. The effect of epilepsy or diabetes mellitus on the risk of automobile accidents. N Engl J Med 1991;324:22-6.
59. Laberge-Nadeau C, Dionne G, Ekoe JM, et al. Impact of diabetes on crash risks of truck-permit holders and commercial drivers. Diabetes Care 2000;23:612-17.
60. Lonnen KF, Powell RJ, Taylor D, et al. Road traffic accidents and diabetes: insulin use does not determine risk. Diabet Med 2008;25:578-84.
61. Watson WA, Currie T, Lemon JS, et al. Driving and insulin-treated diabetes: who knows the rules and recommendations? Pract Diabetes Int 2007;24:201-6.
62. Zammitt NN, Warren RE, Deary IJ, et al. Delayed recovery of cognitive function following hypoglycemia in adults with type 1 diabetes: effect of impaired awareness of hypoglycemia. Diabetes 2008;57:732-6.
63. Van den BG, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
64. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39.
65. Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 2009;35:1738-48.
66. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97.
67. ADA. Standards of medical care in diabetese2009. Diabetes Care 2009;32(Suppl 1):S13-61.
68. NICE. National Guidelines for the Management of Blood Glucose Levels in People with Type 2 Diabetes. NICE, 2002. Ref Type: Generic.
69. Clarke WL, Cox DJ, Gonder-Frederick LA, et al. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 1995;18:517-22.
70. Veneman T, Mitrakou A, Mokan M, et al. Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes 1993;42:1233-7.
71. Korsatko S, Habacher W, Rakovac I, et al. Evaluation of a teaching and treatment program in over 4,000 type 2 diabetic patients after introduction of reimbursement policy for physicians. Diabetes Care 2007;30:1584-6.
72. Samann A, Muhlhauser I, Bender R, et al. Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. Diabetologia 2005;48:1965-70.
73. Hopkins D, lawrence IG, Mansell P, et al. DAFNE (Dose Adjustment For Normal Eating) training delivered in routine clinical practice is associated with significant improvements in measure of quality of life and psychological distress. Diabet Med 2008;25(Suppl 1):A47. Ref Type: Abstract.
74. Lawrence IG, Hopkins D, Mansell P, et al. DAFNE (Dose Adjustment For Normal Eating) training delivered in routine clinical practice is associated with a significant improvement in glycaemic control and a reduction in severe hypoglycaemia. Diabet Med 2008;25(Suppl 1):P115. Ref Type: Abstract.
75. Cox DJ, Gonder-Frederick L, Julian D, et al. Intensive versus standard blood glucose awareness training (BGAT) with insulin-dependent diabetes: mechanisms and ancillary effects. Psychosom Med 1991;534:453-62.
76. Cox DJ, Kovatchev B, Koev D, et al. Hypoglycemia anticipation, awareness and treatment training (HAATT) reduces occurrence of severe hypoglycemia among adults with type 1 diabetes mellitus. Int J Behav Med 2004;11:212-18.
77. Smith CB, Choudhary P, Pernet A, et al. Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit. Diabetes Care 2009;32:1196-8.
78. Brunelle BL, Llewelyn J, Anderson JH Jr, et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998;21:1726-31.
79. Ashwell SG, Amiel SA, Bilous RW, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med 2006;23:285-92.
80. De LI, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005;7:73-82.
81. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-7.
82. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes A meta-analysis. Diabetes Res Clin Pract 2008;81:184-9.
83. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006;(2):CD003287.
84. NICE. Diabetes Insulin Pump Therapy. NICE, 2008.
85. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765-74.
86. Hirsch IB, Bode BW, Garg S, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005;28:533-8.
87. Garg SK, Walker AJ, Hoff HK, et al. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technol Ther 2004;6:9-15.
88. Bolli GB, Kerr D, Thomas R, et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009;32:1170-6.
89. Bode B, Gross K, Rikalo N, et al. Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system. Diabetes Technol Ther 2004;6:105-13.
90. Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 2006;29:44-50.
91. JDRF Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464-76.
92. JDRF Continuous Glucose Monitoring Study Group. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009;32:1378-83.
93. NICE. Type 1 Diabetes in Adults. 2004 http://www.nice.org.uk/nicemedia/pdf/CG015adultsquickrefguide.pdf.